A Multiplexed, Next Generation Sequencing Platform for High-Throughput Detection of SARS-CoV-2
By
Marie-Ming Aynaud,
J. Javier Hernandez,
Seda Barutcu,
Ulrich Braunschweig,
Kin Chan,
Joel D. Pearson,
Daniel Trcka,
Suzanna L. Prosser,
Jaeyoun Kim,
Miriam Barrios-Rodiles,
Mark Jen,
Siyuan Song,
Jess Shen,
Christine Bruce,
Bryn Hazlett,
Susan Poutanen,
Liliana Attisano,
Rod Bremner,
Benjamin J. Blencowe,
Tony Mazzulli,
Hong Han,
Laurence Pelletier,
Jeffrey L Wrana
Posted 20 Oct 2020
medRxiv DOI: 10.1101/2020.10.15.20212712
Population scale sweeps of viral pathogens, such as SARS-CoV-2, that incorporate large numbers of asymptomatic or mild symptom patients present unique challenges for public health agencies trying to manage both travel and local spread. Physical distancing is the current major strategy to suppress spread of the disease, but with enormous socio-economic costs. However, modelling and studies in isolated jurisdictions suggest that active population surveillance through systematic molecular diagnostics, combined with contact tracing and focused quarantining can significantly suppress disease spread1-3 and has significantly impacted disease transmission rates, the number of infected people, and prevented saturation of the healthcare system4-7. However, reliable systems allowing for parallel testing of 10-100,000s of patients in larger urban environments have not yet been employed. Here we describe "COVID-19 screening using Systematic Parallel Analysis of RNA coupled to Sequencing" (C19-SPAR-Seq), a scalable, multiplexed, readily automated next generation sequencing (NGS) platform8 that is capable of analyzing tens of thousands of COVID-19 patient samples in a single instrument run. To address the strict requirements in clinical diagnostics for control of assay parameters and output, we employed a control-based Precision-Recall and predictive Receiver Operator Characteristics (coPR) analysis to assign run-specific quality control metrics. C19-SPAR-Seq coupled to coPR on a trial cohort of over 600 patients performed with a specificity of 100% and sensitivity of 91% on samples with low viral loads and a sensitivity of > 95% on high viral loads associated with disease onset and peak transmissibility. Our study thus establishes the feasibility of employing C19-SPAR-Seq for the large-scale monitoring of SARS-CoV-2 and other pathogens.
Download data
- Downloaded 424 times
- Download rankings, all-time:
- Site-wide: 56,397
- In public and global health: 632
- Year to date:
- Site-wide: 9,735
- Since beginning of last month:
- Site-wide: 15,690
Altmetric data
Downloads over time
Distribution of downloads per paper, site-wide
PanLingua
News
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!